The $10 Stock at the Center of Trump's $100 Trillion Move

Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Vandana Singh
July 07, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPR) stock is experiencing a steep decline on Monday, plummeting by nearly 55%. This significant drop is accompanied by an exceptionally high trading volume of 9.9 million shares, vastly exceeding its average daily volume of 251.9K, according to data from Benzinga Pro.

What Happened?

The company reported updated data from the BEACON Phase 1b/2a study of subcutaneous briquilimab in adult chronic spontaneous urticaria (CSU) participants and provided an update on the program. It reported preliminary data in January.

The primary endpoints are briquilimab’s safety and tolerability, and the secondary endpoints are focused on clinical activity and PK/PD.

Also Read: InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

Primary measurements used to assess clinical activity were the sum of the Hives Severity Score and the daily Itch Severity Score (ISS), as measured via the Urticaria Activity Score over 7 days (UAS7) on a 0 to 42-point scale.

Briquilimab administration resulted in disease control in the 240mg and 360mg single-dose cohorts.

Eight of nine (89%) participants enrolled across both cohorts achieved a complete response, and seven of nine (78%) achieved a clinical response by week 2.

Reductions in UAS7 scores were reported with a mean change from baseline at 4 weeks of 28.3 points in the 240mg single-dose cohort and 22.9 points in the 360mg single-dose cohort.

In addition, BEACON participants who rolled over into the open-label extension study dosing at 180mg Q8W demonstrated clinical efficacy with 8 of 11 (73%) participants achieving a complete response at 12 weeks.

Results from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question.

The company is investigating the drug product lot in question. It expects to have the investigation results in the coming weeks.

Key observations noted in those 10 patients were lower than expected drops in mean tryptase levels and no discernable impact on UAS7 scores. The 2 participants enrolled in the cohorts that have been confirmed as being dosed with drug product from a different lot both achieved complete response.

The company also plans to enroll an additional 10-12 patients across the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts to ensure a robust data set to inform the Phase 2b CSU study.

Data from the additional BEACON patients is expected in the fourth quarter of 2025, and commencement of the Phase 2b study is now expected in mid-2026.

The company has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN trial evaluating briquilimab in asthma.

Why It Matters?

To focus resources on advancing briquilimab in CSU, the company is halting the asthma study and pausing development.

In addition, the company is halting development in SCID and will implement several other cost-cutting measures, including a potential restructuring, to extend the runway and reduce expenses.

Briquilimab treatment also resulted in deep and durable disease control in the open-label extension study evaluating briquilimab at 180mg Q8W, with 8 of 11 participants (73%) achieving a complete response at the week 12 assessment.

Substantial reductions in tryptase were observed as early as the week 1 assessment and were correlated with the onset of clinical responses. Tryptase levels below the lower limit of quantification were reported for 8 of 10 (80%) participants across the 240mg and 360mg single-dose cohorts.

Briquilimab was tolerated well in the BEACON study and the open-label extension, with no dose-limiting toxicities observed.

Price Action: JSPR stock is down 54.5% at $3.08 at the last check on Monday.

Read Next:

Photo by PeopleImages.com – Yuri A via Shutterstock

Continue Reading...

Popular

Nissan racks up red ink, but the Japanese automaker promises a return to profit later this year

TOKYO (AP) — Japanese automaker Nissan sank into a 115.8 billion yen ($782 million) loss for April-June, but promised Wednesday to return to profitability later this year.

Trump Says 5 Jets Downed During India-Pakistan Conflict: '...Shot Out Of The Air'

President Donald Trump during a dinner with Republican lawmakers stated, that up to 5 jets were shot down during the India-Pakistan conflict.

Is Elon's Empire Crumbling? - Ad

Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after October 23rd, it may be too late.

New Jersey US Attorney Fired After Being Chosen Over Former Trump Lawyer Alina Habba

The U.S. Attorney for the District of New Jersey, Desiree Leigh Grace, has been dismissed by the Justice Department.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Cathie Wood's Ethereum Double-Down: Ark Bets $7.9 Million On ETH-Staking ETF Buy While Selling Coinbase At Highs

On Wednesday, Cathie Wood-led Ark Invest executed significant trades, including substantial purchases in Tempus AI Inc. (NASDAQ:TEM), NVIDIA Corp. (NASDAQ:NVDA), 3iQ Ether Stakin

Palantir's Partner Is Taking Off - Ad

Palantir's stock is rising, but their new partner is moving even faster after a surprise announcement. AI meets real-world security.

Allianz Life confirms data breach affecting majority of 1.4M US customers

MINNEAPOLIS (AP) — Hackers gained access to personal data on the majority of the 1.4 million customers of Allianz Life Insurance Company of North America, the company confirmed Saturday.

Investing Legend Hints the End May Be Near for These 3 Iconic Stocks - Ad

Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.

Russia insists on achieving Ukraine goals despite Trump's ultimatum

Russia is open to peace with Ukraine, but achieving its goals remains a priority, Kremlin spokesman Dmitry Peskov said Sunday, days after U.S. President to agree to a ceasefire or .

Brace Yourself for Jeff Bezos' "Amazon Helios" - Ad

Amazon delivers 20 million packages a day... powers some of the most popular websites... delivers medication to half of the U.S. population... and even produces award-winning films and TV shows. But a Wall Street legend -- twice featured on 60 Minutes -- predicts that "Amazon Helios" will be bigger than all of those... COMBINED.

After years of tough rules on liquids and footwear, US air travel may be on the cusp of a new era

NEW YORK (AP) — When limits on liquids were introduced at TSA checkpoints across the country in 2006, bins overflowed with bottled water, toothpaste, shaving cream and so much more. Nearly two decades later, travelers are much more accustomed to the “3-1-1” regulations" governing the size of the liquids they're flying with, but scenes of passengers guzzling a beverage before putting their bags through the screening machines are still common.

The Last Time This Warning Flashed, S&P 500 Crashed The Most Since 2008

A rare warning signal has reappeared in the market, with a low bull-bear spread and high investor indecision.

Tap Into the $65B 'Shroom Boom' - Ad

People are rapidly discovering how mushrooms can enhance brain function, gut health, immunity, and more. The only thing holding them back? A simple way to grow them. Hypha Labs built a compact countertop device to solve exactly that.

Want To Bet Bigger On UnitedHealth? Now There's A Cheaper Way

New UNHG ETF offers 200% daily exposure to UnitedHealth Group with low expense ratio. Themes ETFs adds to roster with 20 single-stock leveraged ETFs.

Nvidia-Supplier Taiwan Semiconductor On A Roll, Profit Explodes With Strong Margin Growth

Taiwan Semiconductor (TSM) reports strong Q2 results and expects continued growth in demand for advanced processor technologies, with revenue guidance of $31.8 billion to $33.0 billion for Q3.

Palantir Just Made a Power Move - Ad

The data giant inked a deal with a company that's already deployed nationwide. It is real-world security.

Circle CEO: Stablecoins Are Going Mainstream — Fast

Jeremy Allaire, CEO of Circle Internet Group, Inc. (NYSE:CRCL), is offering a compelling vision for the future of digital finance and the role of stablecoins in the global economy.

Feihe Struggles Amid China's Dairy Oversupply And Falling Birth Rates

Declining birth rates and China's slowing economy are taking a toll on the company and its peers as they grapple with oversupply and asset impairments on excess inventory

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

Elon Musk Changed His Number, Became Unreachable After Trump Feud, Reveals Speaker Mike Johnson: 'I Sent Him A Long Text Message, And Then...'

Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk has reportedly changed his phone number following a fued with President Donald Trump and disagreement with Speaker Mike Johnson over the Republican's tax-and-spending bill.

What's inside Elon's building in Memphis will shock you - Ad

Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the August 1st funding window closes.

The $10 Stock at the Center of Trump's $100 Trillion Move - Ad

Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.

Oklo Stock Hit A New 52-Week High Today: What's Driving The Action?

Shares of advanced nuclear technology company Oklo are trading higher Thursday. The company announced a strategic alliance with Liberty Energy on Wednesday.

Is Elon's Empire Crumbling? - Ad

Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after October 23rd, it may be too late.

Japanese leader Ishiba vows to remain despite speculation, says he will focus on new US trade deal

TOKYO (AP) — Prime Minister on Wednesday vowed to remain in power to oversee the implementation of a , despite media speculation and growing calls for him to resign after a .

Stellantis warns of $2.7 billion loss for 1st half of 2025 due to tariffs and some big charges

Stellantis, the maker of Jeep and Ram vehicles, says its preliminary estimates show a 2.3 billion euros ($2.68 billion) net loss in the first half of the year due to U.S. tariffs and some hefty charges.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

Carney Faces Cross-Border Pressure Amid High-Stakes US Trade Talks

Carney faces growing criticism at home as Trump threatens steep tariffs amid tense Canada-U.S. trade negotiations.

Palantir's Partner Is Taking Off - Ad

Palantir's stock is rising, but their new partner is moving even faster after a surprise announcement. AI meets real-world security.

The government was once a steady partner for nonprofits. That's changing

Dawn Price signs rent checks worth about $160,000 every month for 79 people that her nonprofit helps house in Laguna Beach, California.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service